Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 60-69 , January 2002

18F-deoxyglucose and the assessment of myocardial viability

  • Heinrich R. Schelbert

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Heinrich R. Schelbert, MD, UCLA School of Medicine, 23-120 CHS, Los Angeles, CA 90095-1735.

References 

  1. Phelps ME, Hoffman EJ, Selin CE, et al. Investigation of [18F] 2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978;19:1311–1319
  2. Phelps ME, Hoffman EJ, Mullani NA, et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16:210–224
  3. Hoffman EJ, Phelps ME, Weiss ES, et al. Transaxial tomographic imaging of canine myocardium with 11C-palmitic acid. J Nucl Med. 1977;18:57–61
  4. Ratib O, Phelps ME, Huang SC, et al. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med. 1982;23:577–586
  5. Bøtker HE, Goodwin GW, Holden JE, et al. Myocardial glucose uptake measured with fluorodeoxyglucose: A proposed method to account for variable lumped constants. J Nucl Med. 1999;40:1186–1196
  6. Hariharan R, Bray M, Ganim R, et al. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation. 1995;91:2435–2444
  7. Gambhir SS, Schwaiger M, Huang SC, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and Fluorine-18 deoxyglucose. J Nucl Med. 1989;30:359–366
  8. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993;20:308–318
  9. Bing RJ. The metabolism of the heart. In: Harvey Lectures. New York, NY: Academic Press; 1954;p. 27–70
  10. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1985;5:584–590
  11. Choi Y, Hawkins R, Huang S, et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med. 1991;32:733–738
  12. Nuutila P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest. 1992;89:1767–1774
  13. Randle RJ, Garland BP, Hales CN, et al. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet. 1963;1:785–789
  14. Gropler R, Siegel B, Lee K, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med. 1990;31:1749–1756
  15. Opie LH. Myocardial ischemia—metabolic pathways and implications of increased glycolysis. Cardio Drugs Ther. 1990;4:777–790
  16. Schön HR, Schelbert HR, Najafi A, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. II. Kinetics of C-11 palmitic acid in acutely ischemic myocardium. Am Heart J. 1982;103:548–561
  17. Schelbert HR, Henze E, Schön HR, et al. C-11 palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. IV. In vivo demonstration of impaired fatty acid oxidation in acute myocardial ischemia. Am Heart J. 1983;106:736–750
  18. Buxton D, Vaghaiwalla-Mody F, Krivokapich J, et al. Quantitative assessment of prolonged metabolic abnormalities in reperfused canine myocardium. Circulation. 1992;85:1842–1856
  19. Schelbert HR, Phelps ME, Selin C, et al. Regional myocardial ischemia assessed by 18Fluoro-2-deoxyglucose and positron emission computed tomography. In: Kreuzer H, Parmley WW, Rentrop P, et al. editor. Quantification of Myocardial Ischemia. New York: Gerhard Witzstrock Publishing House; 1980;p. 437–447
  20. Schwaiger M, Brunken R, Grover-McKay M, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol. 1986;8:800–808
  21. Czemin J, Porenta G, Brunken R, et al. Regional blood flow oxidative metabolism, and glucose utilization in patients with recent myocardial infarction. Circulation. 1993;88:884–895
  22. Schwaiger M, Neese RA, Araujo L, et al. Sustained nonoxidative glucose utilization and depletion of glycogen in reperfused canine myocardium. J Am Coll Cardiol. 1989;13:745–754
  23. Marshall RC, Tillisch JH, Phelps ME, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation. 1983;67:766–778
  24. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1987;72:V123–V135
  25. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149
  26. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578–588
  27. Flameng W, Suy R, Schwarz F, et al. Ultrastructural correlates of left ventricular contraction abnormalities in patients with chronic ischemic heart disease: Determinations of reversible segmental asynergy postrevascularization surgery. Am Heart J. 1981;102:846–857
  28. Borgers M, Ausma J. Structural aspects of the chronic hibernating myocardium in man. Basic Res Cardiol. 1995;90:44–46
  29. Ausma J, Feurst D, Thonae F, et al. Molecular changes of titin in left ventricular dysfunction as a result of chronic hihernation. J Mol Cell Cardiol. 1995;27:1203–1212
  30. Schwaiger M, Sun D, Deeb G, et al. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease (CAD). Circulation. 1994;90:I–113
  31. Ausma J, Thonae F, Dispersyn GD, et al. Dedifferentiated cardiomyocytes from chronic hibernating myocardium are ischemia-tolerant. Mol Cell Biochem. 1998;186:159–168
  32. Lopaschuk G, Stanley W. Glucose metabolism in the ischemic heart. Circulation. 1997;95:313–315
  33. Elsässer A, Schlepper M, Kleovekorn WP, et al. Hibernating myocardium: An incomplete adaptation to ischemia. Circulation. 1997;96:2920–2931
  34. Elsässer A, Decker E, Kostin S, et al. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol Cell Biochem. 2000;213:17–28
  35. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–888
  36. Carrel T, Jenni R, Haubold-Reuter S, et al. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg. 1992;6:479–484
  37. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med. 1992;19:874–881
  38. Tamaki N, Yonekura Y, Yamashita K, et al. SPECT thallium-201 tomography and positron tomography using N-13 ammonia and F-18 fluorodeoxyglucose in coronary heart disease. Am J Cardiol Imaging. 1989;3:3–9
  39. Tamaki N, Yonekura Y, Yamashita K, et al. Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography. J Cardiol. 1991;21:193–201
  40. Marwick T, Nemec J, Lafont A, et al. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992;69:854–859
  41. Marwick T, MacIntyre W, Lafont A, et al. Metabolic responses of hibernating and infarcted myocardium to revascularization: A follow-up study of regional perfusion, function, and metabolism. Circulation. 1992;85:1347–1353
  42. Marwick T, Zuchowski C, Lauer M, et al. Functional status and quality of life in patients with heart failure undergoing coronary bypass surery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33:750–758
  43. Bax JJ, Cornel JH, Visser FC, et al. F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. J Nucl Cardiol. 1997;4:302–308
  44. Bax JJ, Cornel JH, Visser FC, et al. Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization. J Nucl Med. 1998;39:1481–1486
  45. Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol. 1997;30:377–383
  46. Bax J, Cornel J, Visser F, et al. Quantitative analysis of FDG and Tl-201 SPECT for the prediction of functional outcome after revascularization. J Nucl Med. 1995;36:36P
  47. Maes AF, van de Werf F, Mesotten LV, et al. Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. J Am Coll Cardiol. 2001;37:30–36
  48. Maes A, Mortelmans L, Nuyts J, et al. Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute myocardial infarction. Eur Heart J. 1997;18:954–962
  49. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68:785–795
  50. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with low ejection fraction. N Engl J Med. 1985;312:1665–1671
  51. Eitzman D, Al-Aouar Z, Vom Dahl J, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559–565
  52. Yoshida K, Gould K. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol. 1993;22:984–997
  53. Tamaki N, Kawamoto M, Takahasi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging. J Am Coll Cardiol. 1993;22:1621–1627
  54. Di Carli M, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527–533
  55. Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116:997–1004
  56. Lee K, Marwick T, Cook S, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium infarction. Circulation. 1994;90:2687–2694
  57. [see comments] Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693–1700
  58. Beanlands RS, Hendry PJ, Masters RG, et al. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imagine. Circulation. 1998;98:II51–II56
  59. Pagano D, Townend JN, Littler WA, et al. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg. 1998;115:791–799
  60. Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol. 2001;87:1096–1099Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol. 2001;87:A6
  61. Landoni C, Lucignani G, Paolini G, et al. Assessment of CABG-related risk in patients with CAD and LVD. Contribution of PET with [18F]FDG to the assessment of myocardial viability. J Cardiovasc Surg. 1999;40:363–372
  62. Fath-Ordoubadi F, Pagano D, Marinho NV, et al. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction. Am J Cardiol. 1998;82:26–31
  63. Flameng WJ, Shivalker B, Spiessens B, et al. PET scan predicts recovery of left ventricular function after coronary artery bypass operation. Ann Thorac Surg. 1997;64:1694–1701
  64. Schöder H, Campisi R, Ohtake T, et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol. 1999;33:1328–1337
  65. Dreyfus G, Duboc D, Blasco A, et al. Coronary surgery can be an alternative to heart transplantation in selected patients with end-stage ischemic heart disease. Eur J Cardiothorac Surg. 1993;7:482–487
  66. Hata T, Nohara R, Fujita M, et al. Noninvasive assessment of myocardial viability by positron emission tomography with 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation. 1996;94:1834–1841
  67. Wolpers H, Burchert W, van den Hoff J, et al. Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Circulation. 1997;95:1417–1424
  68. Akinboboye Oo, Idris O, Cannon PJ, et al. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Am J Cardiol. 1999;83:1271–1274Akinboboye Oo, Idris O, Cannon PJ, et al. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Am J Cardiol. 1999;83:A9
  69. Nienaber C, Brunken R, Sherman C, et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol. 1991;18:966–978
  70. Vanoverschelde JL, Depre C, Gerber BL, et al. Time course of functional recovery after coronary artery bypass graft surgery in patients with chronic left ventricular ischemic dysfunction. Am J Cardiol. 2000;85:1432–1439
  71. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92:3436–3444
  72. Bax JJ, Wijns W, Cornel JH, et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: Comparison of pooled data. J Am Coll Cardiol. 1997;30:1451–1460
  73. Dreyfus GD, Duboc D, Blasco A, et al. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization. Ann Thorac Surg. 1994;57:1402–1408
  74. Auerbach MA, Scheoder H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation. 1999;99:2921–2926
  75. Mäki MT, Haaparanta MT, Luotolahti MS, et al. Fatty acid uptake is preserved in chronically dysfunctional but viable myocardium. Am J Physiol. 1997;273:H2473–H2480
  76. Stone C, Martin C, Mueller B, et al. Comparison of myocardial uptake of copper pyruvaldehyde thiosemicarbazone with N-13 ammonis in humans by PET. J Nucl Med. 1991;32:999
  77. Duong T, Hendi P, Fonarow G, et al. Role of positron emission tomographic assessment of myocardial viability in the management of patients who are referred for cardiac transplantation. Circulation. 1995;92:I–123

† Operated for the US Department of Energy by the University of California under contract DE-AC03-76-SF00012. Supported in part by the Director of the Office of Energy Research, Office of Health and Environmental Research, Washington, DC, and by Research Grant HL 33177, National Institutes of Health, Bethesda, MD.

PII: S0001-2998(02)80040-X

doi: 10.1053/snuc.2002.29274

Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 60-69 , January 2002

Article Tools